Introduction

Description of MDL No. 15-MD-2642

This multidistrict litigation consists of a significant number of cases currently pending before this Court involving fluorquinolones. Fluoroquinolones are antibiotics used to treat a variety of bacterial infections, including upper respiratory infections. Plaintiffs have been prescribed a Fluoroquinolone, and allege that it causes neuropathy. They claim that defendants' warnings about this alleged side effect were inadequate.

Defendants Bayer Healthcare Pharmaceuticals, Inc, Merck & Co, Inc., Johnson & Johnson, Janssen Research & Development LLC, McKesson Corporation, Shering Corporation, and Bayer Corporation allegedly developed, manufacture and market fluoroquinolones. Defendants deny that fluoroquinolones are defective or unreasonably dangerous. Defendants also deny that they failed to provide adequate warnings.

The Judicial Panel on Multidistrict Litigation determined that centralizing the Fluoroquinolone Neuropathy cases was appropriate. Based on a number of factors, the Judicial Panel determined that the District of Minnesota was an appropriate forum. All Fluoroquinolone Neuropathy federal cases have been ordered transferred to the District of Minnesota, and assigned to the Honorable John R. Tunheim as MDL No. 15-2642.

Judge Tunheim is coordinating discovery and other pretrial matters in these cases. Subsequent Fluoroquinolone Neuropathy cases filed in federal court will ordinarily be transferred to the District of Minnesota and become part of MDL No. 15-2642 as “tag along” cases. When discovery and other pretrial matters have been concluded, the cases that constitute MDL No. 15-2642, unless otherwise resolved, will be transferred back to the districts in which they were originally filed for trial or other proceedings................